Published in PLoS One on October 10, 2012
BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther (2014) 1.30
Mutant SOD1 Increases APP Expression and Phosphorylation in Cellular and Animal Models of ALS. PLoS One (2015) 0.77
Alzheimer's disease: genes, proteins, and therapy. Physiol Rev (2001) 19.19
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol (1999) 7.69
Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci (2006) 6.52
Alzheimer's disease. Lancet (2011) 5.35
GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature (2003) 4.97
BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci (2001) 4.54
Intraneuronal Abeta42 accumulation in human brain. Am J Pathol (2000) 3.83
Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci (2010) 3.61
Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res (1994) 3.26
Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol (2002) 3.23
Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A (2005) 2.95
Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci (1994) 2.81
Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron (2010) 2.68
Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta (2005) 2.46
Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci (1993) 2.10
Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol (1999) 2.08
Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease. Neurobiol Aging (2005) 2.06
Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci U S A (2009) 2.04
Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. J Neurosci (2010) 1.93
C-terminal fragments of amyloid precursor protein exert neurotoxicity by inducing glycogen synthase kinase-3beta expression. FASEB J (2003) 1.90
Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci (2005) 1.85
Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing. Neuron (2008) 1.59
The role of tau in neurodegeneration. Mol Neurodegener (2009) 1.54
Identification of beta-secretase (BACE1) substrates using quantitative proteomics. PLoS One (2009) 1.52
Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J Biol Chem (2000) 1.52
Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. J Cell Sci (1996) 1.49
Comparison of four staining methods on the detection of neuritic plaques. Acta Neuropathol (1989) 1.30
Patterns of gliosis in Alzheimer's disease and aging cerebrum. Glia (1989) 1.22
Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol (2007) 1.21
Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol (2009) 1.19
Maintained synaptophysin immunoreactivity in Tg2576 transgenic mice during aging: correlations with cognitive impairment. Brain Res (2002) 1.19
A nontransgenic mouse model shows inducible amyloid-beta (Abeta) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade. Proc Natl Acad Sci U S A (2004) 1.18
Mitochondrial dysfunction and accumulation of the β-secretase-cleaved C-terminal fragment of APP in Alzheimer's disease transgenic mice. Neurobiol Dis (2011) 1.13
Activation of the amyloid cascade in apolipoprotein E4 transgenic mice induces lysosomal activation and neurodegeneration resulting in marked cognitive deficits. J Neurosci (2008) 1.11
Glycogen synthase kinase-3beta, or a link between amyloid and tau pathology? Genes Brain Behav (2008) 1.10
Regulation of Alzheimer's disease amyloid-beta formation by casein kinase I. Proc Natl Acad Sci U S A (2007) 1.09
Inhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies. Proc Natl Acad Sci U S A (2005) 1.08
Cognitive and non-cognitive behaviors in the triple transgenic mouse model of Alzheimer's disease expressing mutated APP, PS1, and Mapt (3xTg-AD). Behav Brain Res (2012) 1.00
Beta-secretase as a target for the treatment of Alzheimer's disease. J Neurosci Res (2002) 0.99
Natural history of Alzheimer's disease. Aging (Milano) (2001) 0.98
Increase in the density of resting microglia precedes neuritic plaque formation and microglial activation in a transgenic model of Alzheimer's disease. Cell Death Dis (2010) 0.96
BACE inhibitor reduces APP-beta-C-terminal fragment accumulation in axonal swellings of okadaic acid-induced neurodegeneration. Neurobiol Dis (2006) 0.93
Emerging Alzheimer's disease therapies: inhibition of beta-secretase. Neurobiol Aging (2002) 0.90
Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels. Neurodegener Dis (2007) 0.88
Brain infarction and the clinical expression of Alzheimer disease. JAMA (1997) 0.79
Immunomodulation of AβPP processing alleviates amyloid-β-related pathology in Alzheimer's disease transgenic mice. J Alzheimers Dis (2010) 0.77
Filamentous phage as vector-mediated antibody delivery to the brain. Proc Natl Acad Sci U S A (2002) 1.38
Inhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies. Proc Natl Acad Sci U S A (2005) 1.08
Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide. J Neurosci Res (2006) 1.01
Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization. Vaccine (2003) 0.95
Generation of antibodies against prion protein in wild-type mice via helix 1 peptide immunization. J Neuroimmunol (2003) 0.91
EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials. J Mol Neurosci (2004) 0.90
Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels. Neurodegener Dis (2007) 0.88
Antibodies to beta-amyloid decrease the blood-to-brain transfer of beta-amyloid peptide. Exp Biol Med (Maywood) (2002) 0.86
Contamination of coagulation factor concentrates with human parvovirus B19 genotype 1 and 2. Thromb Haemost (2004) 0.84
Immunotherapy for Alzheimer's disease: attacking amyloid-beta from the inside. Trends Immunol (2007) 0.83
Stimulation of endogenous neurogenesis by anti-EFRH immunization in a transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2007) 0.81
Modulation effect of filamentous phage on alpha-synuclein aggregation. Biochem Biophys Res Commun (2009) 0.80
Single chain antibody against the common epitope of mutant p53 restores wild-type activity to mutant p53 protein. FEBS Lett (2005) 0.80
Filamentous phages reduce alpha-synuclein oligomerization in the membrane fraction of SH-SY5Y cells. Neurodegener Dis (2010) 0.79
A novel immunotherapy for Alzheimer's disease: antibodies against the beta-secretase cleavage site of APP. Curr Alzheimer Res (2007) 0.79
Antigen-specific therapy of EAE via intranasal delivery of filamentous phage displaying a myelin immunodominant epitope. J Neuroimmunol (2010) 0.78
Multifunctional Effect of Human Serum Albumin Reduces Alzheimer's Disease Related Pathologies in the 3xTg Mouse Model. J Alzheimers Dis (2015) 0.77
Inhibition of amyloid precursor protein beta-secretase cleavage site affects survival and motor functions of amyotrophic lateral sclerosis transgenic mice. Neurodegener Dis (2012) 0.77
The impact of N-nitrosomelatonin as nitric oxide donor in cell culture experiments. J Pineal Res (2008) 0.77
Immunomodulation of AβPP processing alleviates amyloid-β-related pathology in Alzheimer's disease transgenic mice. J Alzheimers Dis (2010) 0.77
Generation of anti-beta-amyloid antibodies via phage display technology. Vaccine (2004) 0.76
Deglycosylation of anti-beta amyloid antibodies inhibits microglia activation in BV-2 cellular model. Am J Alzheimers Dis Other Demen (2005) 0.76
Inhibition of amyloid precursor protein processing leads to downregulation of apoptotic genes in Alzheimer's disease animal models. Neurodegener Dis (2013) 0.75
TAR1, a human anti-p53 single-chain antibody, restores tumor suppressor function to mutant p53 variants. J Immunother (2010) 0.75
A neuroimmunologist's perspective on Alzheimer's disease therapy. Expert Rev Neurother (2007) 0.75